Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Using Integrative Medicine Approaches for Cancer-Related Fatigue

September 12, 2018
By Lori Smith, BSN, MSN, CRNP
Article

Breast and gynecologic cancer patients undergoing chemotherapy may experience improvement in cancer-related fatigue with integrative medicine approaches.

Breast and gynecologic cancer patients undergoing chemotherapy may experience improvement in cancer-related fatigue with integrative medicine approaches, explained researchers of a recent study. The researchers’ objective was to evaluate the effect of integrative medicine on those with both early and advanced breast and gynecologic malignancies receiving chemotherapy as treatment. What they found was that the use of integrative medicine may help alleviate some of the fatigue experienced by these patients.

“Fatigue is almost always multifactorial. Chemotherapy can increase fatigue by causing anemia, poor sleep, suppression of endogenous corticosteroids, release of pro-inflammatory cytokines, and poor nutrition from reduced appetite and increased nausea,” said Gary Deng, MD, PhD, medical director of the integrative medicine service at Memorial Sloan Kettering Cancer Center in New York, who was not involved in this research.

The study, published in Supportive Care in Cancer, which was conducted between June 2013 and May 2016, included 258 patients with early- to late-stage gynecologic or breast cancers undergoing treatment with adjuvant, neoadjuvant, or palliative chemotherapy. Study participants were evaluated at baseline and then at their 6- and 12-week follow-up appointments. Assessments included evaluation of quality of life, cancer-related fatigue, and routine hemoglobin levels. In addition, the relative dose intensity was assessed during the 6- and 12-week visits.

Researchers led by Eran Ben-Arye, MD, of the integrative oncology program at Lin and Carmel Medical Centers, Clalit Health Services in Haifa, Israel, found improvement in fatigue at both the 6- and 12-week follow-up evaluations in study participants treated with integrative medicine modalities, such as acupuncture, mind-body-spirit therapies, touch/movement therapies, and herbal/nutritional interventions. The researchers noted that acupuncture was used to treat the 120 study participants who were optimally assessed during the trial, adding that most of the participants underwent simultaneous treatment with at least two integrative medicine methods.

“It is imperative to take a holistic approach in treating [fatigue],” noted Deng. “The ‘one-symptom, one-drug’ approach would miss the mark. Therefore, we have to take a multidisciplinary approach to address all contributing factors.”

Although fatigue levels improved in the treatment arm of the study, hemoglobin levels were noted to decline in those treated with integrated medicine. “The relationship between improved fatigue levels despite reduced hemoglobin levels in complementary and alternative medicine–treated patients, which was reported in the present study, needs to be better understood,” noted the researchers.

“Because of the complexity in managing fatigue, research in this area is challenging. What would constitute the combination of “secret ingredients” that produces optimal clinical benefit is very difficult to tease out. On the other hand, fatigue is so prevalent among cancer patients, and we currently have no reliable treatment that gives us satisfactory results. Any research to explore new approaches would be very much needed,” stressed Deng.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Multidisciplinary care can help ensure that treatment planning does not deviate from established guidelines for inflammatory breast cancer management.
Photographic and written documentation can help providers recognize inflammatory breast cancer symptoms across diverse populations.
The use of guideline-concordant care in breast cancer appears to be more common in White populations than Black populations.
Strict inclusion criteria may disproportionately exclude racial minority populations from participating in breast cancer trials.
Related Content

Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer

Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer

Ariana Pelosci
June 4th 2025
Article

For patients with unresectable vulvar cancer, an improved ORR was observed with pembrolizumab plus cisplatin and RT, followed by maintenance pembrolizumab.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Frontline T-DXd Combo Elicits Meaningful PFS in HER2+ Advanced Breast Cancer

Russ Conroy
June 2nd 2025
Article

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

Russ Conroy
June 1st 2025
Article

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.


Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer

Caroline Seymour
June 1st 2025
Article

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Related Content

Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer

Pembrolizumab/Cisplatin and RT Enhance Responses in Unresectable Vulvar Cancer

Ariana Pelosci
June 4th 2025
Article

For patients with unresectable vulvar cancer, an improved ORR was observed with pembrolizumab plus cisplatin and RT, followed by maintenance pembrolizumab.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.

Frontline T-DXd Combo Elicits Meaningful PFS in HER2+ Advanced Breast Cancer

Russ Conroy
June 2nd 2025
Article

Data from DESTINY-Breast09 may support trastuzumab deruxtecan plus pertuzumab as a frontline standard of care in HER2-positive advanced breast cancer.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.

Sacituzumab Govitecan Combo Shows Pathologic Responses in Early-Stage TNBC

Russ Conroy
June 1st 2025
Article

Data from the NeoSTAR trial showed no new safety signals with sacituzumab govitecan plus pembrolizumab for early-stage triple-negative breast cancer.


Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Camizestrant Enhances PFS vs AI Inhibitor in ER+/HER2– Breast Cancer

Caroline Seymour
June 1st 2025
Article

Camizestrant and continued CDK4/6 inhibition delayed time to QOL deterioration vs SOC therapy in ER+/HER2– advanced breast cancer.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.